PD-1 and PD-1 ligands: from discovery to clinical application
The DOI matches its Crossref record; 133 of the 138 references it cites were found in a registry or an index.
Abstract
Programmed cell death-1 (PD-1, Pdcd1), an immunoreceptor belonging to the CD28/CTLA-4 family negatively regulates antigen receptor signaling by recruiting protein tyrosine phosphatase, SHP-2 upon interacting with either of two ligands, PD-L1 or PD-L2. Because of the wide range of ligand distribution in the body, its biological significance pervades almost every aspect of immune responses including autoimmunity, tumor immunity, infectious immunity, transplantation immunity, allergy and immunological privilege. In this review, we would like to summarize the history of PD-1 research since its discovery and recent findings that suggest promising future for the clinical application of PD-1 agonists and antagonists to various human diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“PD-1 interacts with an SHP2 tyrosine phosphatase domain, leading to dephosphorylation of signaling molecules downstream of the TCR and inhibiting TCR-mediated activation of IL2 production and T-cell proliferation (13).”
From The Next Decade of Immune Checkpoint Therapy (2021) · cites this paper as [13]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
Nguyen, L. T., Radhakrishnan, S., Ćirić, B., Tamada, K., Shin, T., Pardoll, D. M., Chen, L., Rodriguez, M., & Pease, L. R. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20021466 · Cited by 105 · cited 1×
“However, one group reported that cross-linking of PD-L2 induces stimulatory signal in dendritic cells (DCs), resulting in the augmented antigen presentation ( 26 , 27).”
BackgroundRetractedRadhakrishnan, S., Nguyen, L. T., Ćirić, B., Ure, D., Zhou, B., Tamada, K., Dong, H., Tseng, S.-Y., Shin, T., Pardoll, D. M., et al. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.4.1830 · Cited by 73
RetractedFreeman, G. J., Long, A. J., Iwai, Y., Bourque, K., Chernova, T., Nishimura, H., Fitz, L. J., Malenkovich, N., Okazaki, T., Byrne, M. C., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.7.1027 · Cited by 5,294
Self-citationTumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
Dong, H., Strome, S. E., Salomao, D. R., Tamura, H., Hirano, F., Flies, D. B., Roche, P. C., Lu, J., Zhu, G., Tamada, K., et al. (2002) · Nature Medicine · doi:10.1038/nm730 · Cited by 5,025
Tolerance, Danger, and the Extended Family
Matzinger, P. (1994) · Annual Review of Immunology · doi:10.1146/annurev.iy.12.040194.005015 · Cited by 4,820
Restoring function in exhausted CD8 T cells during chronic viral infection
Barber, D. L., Wherry, E. J., Masopust, D., Zhu, B., Allison, J. P., Sharpe, A. H., Freeman, G. J., & Ahmed, R. (2006) · Nature · doi:10.1038/nature04444 · Cited by 3,986
Ishida, Y., Agata, Y., Shibahara, K., & Honjo, T. (1992) · The EMBO Journal · doi:10.1002/j.1460-2075.1992.tb05481.x · Cited by 3,256
Iwai, Y., Ishida, M., Tanaka, Y., Okazaki, T., Honjo, T., & Minato, N. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.192461099 · Cited by 3,203
PD-L2 is a second ligand for PD-1 and inhibits T cell activation
Latchman, Y., Wood, C. R., Chernova, T., Chaudhary, D., Borde, M., Chernova, I., Iwai, Y., Long, A. J., Brown, J. A., Nunes, R., et al. (2001) · Nature Immunology · doi:10.1038/85330 · Cited by 2,955
Self-citationNishimura, H., Nose, M., Hiai, H., Minato, N., & Honjo, T. (1999) · Immunity · doi:10.1016/s1074-7613(00)80089-8 · Cited by 2,749
Self-citation
Cited by
Items 301–400 of 1,001
Ademuyiwa, F. O., Gao, F., Street, C., Chen, I., Northfelt, D., Wesolowski, R., Arora, M., Brufsky, A., Dees, E. C., Santa-Maria, C. A., et al. (2022) · npj Breast Cancer · doi:10.1038/s41523-022-00500-3 · Cited by 69
Dolina, J. S., Sung, S. J., Novobrantseva, T. I., Nguyen, T. M., & Hahn, Y. S. (2013) · Molecular Therapy — Nucleic Acids · doi:10.1038/mtna.2012.63 · Cited by 67
Mahmoudi, M., Aslani, S., Nicknam, M. H., Karami, J., & Jamshidi, A. (2016) · Modern Rheumatology · doi:10.1080/14397595.2016.1206174 · Cited by 68
“Furthermore, association of two SNPs of the PDCD1 gene, PD-1.”
InfluentialBreast Cancer Therapeutics and Biomarkers: Past, Present, and Future Approaches
Schick, J., Ritchie, R. P., & Restini, C. B. A. (2021) · Breast Cancer Basic and Clinical Research · doi:10.1177/1178223421995854 · Cited by 74
Thyroid-related adverse events induced by immune checkpoint inhibitors
Chera, A., Stancu, A. L., & Bucur, O. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1010279 · Cited by 67
Dong, W., Gong, M., Shi, Z., Xiao, J. A., Zhang, J., & Peng, J. (2016) · PLoS ONE · doi:10.1371/journal.pone.0152448 · Cited by 65
“3, which encodes a 50–55 kD type I transmembranous glycoprotein protein [2, 3].”
BackgroundLázár‐Molnár, E., Scandiuzzi, L., Basu, I., Quinn, T. J., Sylvestre, E., Palmieri, E., Ramagopal, U. A., Nathenson, S. G., Guha, C., & Almo, S. C. (2017) · EBioMedicine · doi:10.1016/j.ebiom.2017.02.004 · Cited by 65
“PD-1 was discovered in lymphoid murine cell lines induced to undergo apoptosis by PMA stimulation (Ishida et al., 1992; Okazaki and Honjo, 2007).”
BackgroundPrognostic value of programmed death-ligand 1 (PD-L1) expression in ovarian clear cell carcinoma
Zhu, J., Wen, H., Bi, R., Wu, Y., & Wu, X. (2017) · Journal of Gynecologic Oncology · doi:10.3802/jgo.2017.28.e77 · Cited by 62
“Blockage of PD-L1 expression on tumor cells might activate tumor-specific T cell to kill tumor cells by mediating tumor necrosis factor alpha (TNF-α) and interferon gamma (IFN-γ) [8,9].”
BackgroundHuang, Z.-L., Liu, S., Wang, G.-N., Zheng, S.-H., Ding, S.-R., Tao, Y., Chen, C., Liu, S.-R., Yang, X. L., Chang, H., et al. (2019) · Cancer Cell International · doi:10.1186/s12935-019-0863-5 · Cited by 66
Saxena, K., Herbrich, S. M., Pemmaraju, N., Kadia, T. M., Dinardo, C. D., Borthakur, G. M., Pierce, S. A., Jabbour, E. J., Wang, S. A., Bueso-Ramos, C., et al. (2021) · Cancer · doi:10.1002/cncr.33690 · Cited by 65
“Expression of mRNA does not always correlate with protein expression (including for PDL1 and PDL2) and, to our knowledge, PDL2 surface protein expression has not been extensively characterized on AML blasts.(45) We found that 8 of 9 patients assessed by mass cytometry had >25% PDL2– positive pretreatment blasts (media…”
BackgroundPeng, F., Xiong, L., & Peng, C. Y. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00251 · Cited by 64
“Programmed cell death ligand 1 (PD-L1) expressed in cancer cells is a functional ligand of programmed cell death 1 (PD-1) expressed in immune cells (Okazaki and Honjo, 2007), and high expression of PD-L1 could affect the evasion of host antitumor immunity of cancer cells, potentially abating the efficacy of anticancer…”
BackgroundImmune-Checkpoint Inhibitors in B-Cell Lymphoma
Armengol, M., Santos, J. C., Fernández-Serrano, M., Profitós-Pelejà, N., Ribeiro, M. L., & Roué, G. (2021) · Cancers · doi:10.3390/cancers13020214 · Cited by 65
Guo, W., Gao, H., Li, H., Ge, S., Zhang, F., Wang, L., Shi, H., & Han, A. (2022) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.2c06001 · Cited by 64
Mizugaki, H., Yamamoto, N., Murakami, H., Kenmotsu, H., Fujiwara, Y., Ishida, Y., Kawakami, T., & Takahashi, T. (2016) · Investigational New Drugs · doi:10.1007/s10637-016-0371-6 · Cited by 64
Guo, R., Li, Y., Wang, Z., Bai, H., Duan, J., Wang, S., Wang, L., & Wang, J. (2019) · Cancer Science · doi:10.1111/cas.13989 · Cited by 67
Controversies in the management of hepatocellular carcinoma
Forner, A., da Fonseca, L. G., Díaz‐González, Á., Sanduzzi‐Zamparelli, M., Reig, M., & Bruix, J. (2019) · JHEP Reports · doi:10.1016/j.jhepr.2019.02.003 · Cited by 60
“JHE inflammation are suggested to result in an immunosuppressive phenotype, and some mechanisms of immune evasion are present in the HCC microenvironment.(136) The interest in studying immune checkpoint inhibitors such as PD-1/PDL-1 and CTLA-4 in HCC promptly translated into clinical phases and, actually, early data h…”
BackgroundProgrammed Death-1 Shapes Memory Phenotype CD8 T Cell Subsets in a Cell-Intrinsic Manner
Charlton, J. J., Chatzidakis, I., Tsoukatou, D., Boumpas, D. T., Garinis, G. A., & Mamalaki, C. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1201617 · Cited by 58
PD-L1 and immune escape: insights from melanoma and other lineage-unrelated malignancies
Frydenlund, N., & Mahalingam, M. (2017) · Human Pathology · doi:10.1016/j.humpath.2017.06.012 · Cited by 67
Cutaneous Adverse Events of Targeted Therapies for Hematolymphoid Malignancies
Ransohoff, J. D., & Kwong, B. Y. (2017) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2017.07.005 · Cited by 60
CircRNA–miRNA networks in regulating bone disease
Huang, W., Wu, Y., Qiao, M., Xie, Z., Cen, X. B., Huang, X., & Zhao, Z. (2021) · Journal of Cellular Physiology · doi:10.1002/jcp.30625 · Cited by 57
“…superfamily, PD‐1 is a 288‐amino acid protein that is induced on T cells on activation at a low concentration through the T‐cell antigen receptor and through cytokine receptors (Okazaki & Honjo, 2007), both of which could convey signals to promote the biogenesis of PD‐1 when stimulated by antigens.”
BackgroundNew drug targets in metastatic melanoma
Homet, B., & Ribas, A. (2013) · The Journal of Pathology · doi:10.1002/path.4259 · Cited by 63
“PD-L2, on the contrary, is expressed primarily by antigen-presenting cells [64].”
Beyond the Standard of Care: A Review of Novel Immunotherapy Trials for the Treatment of Lung Cancer
Hall, R. D., Gray, J. E., & Chiappori, A. (2013) · Cancer Control · doi:10.1177/107327481302000105 · Cited by 57
Haas, K. M. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1101990 · Cited by 57
“PD-1, a member of the B7/CD28 family, is expressed by Ag-specific B cells shortly after TI-2 Ag immunization (27) and is well-documented to negatively regulate AgR signaling on both B and T cells following engagement of its ligands, PD-L1 and PD-L2 (28, 29).”
Gibson, A., Ogese, M. O., Sullivan, A. K., Wang, E., Saide, K., Whitaker, P., Peckham, D. G., Faulkner, L., Park, B. K., & Naisbitt, D. J. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1302720 · Cited by 62
“Activation of the PD-1 receptor, which is transiently expressed on activated T cells (15, 16), leads to clustering between TCRs and the phosphatase SHP2, dephosphorylation of TCR signaling, and suppression of Ag-specific T cell responses (17).”
BackgroundWatanabe, S., Hayashi, H., Haratani, K., Shimizu, S., Tanizaki, J., Sakai, K., Kawakami, H., Yonesaka, K., Tsurutani, J., Togashi, Y., et al. (2019) · Cancer Science · doi:10.1111/cas.13860 · Cited by 56
Immunotherapy in Testicular Germ Cell Tumors
Kaľavská, K., Schmidtova, S., Chovanec, M., & Mego, M. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.573977 · Cited by 61
Troiano, G., Caponio, V. C. A., Zhurakivska, K., Arena, C., Pannone, G., Mascitti, M., Santarelli, A., & Muzio, L. L. (2018) · Cell Proliferation · doi:10.1111/cpr.12537 · Cited by 59
Focus on PD-1/PD-L1 as a Therapeutic Target in Ovarian Cancer
Dumitru, A. V., Dobrică, E.-C., Croitoru, A. E., Creţoiu, S. M., & Gașpar, B. S. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232012067 · Cited by 59
“The expression of PD-1 on the surface of many cell types, and especially on tumors, makes it possible, through the interaction between PD-1 and PD-L1, though difficult, to get rid of cancer cells by the mechanisms of the immune system, which leads to the emergence of therapeutic resistance [14,31,64,65].”
BackgroundComponents, Formulations, Deliveries, and Combinations of Tumor Vaccines
Liu, T., Yao, W., Sun, W., Yuan, Y., Liu, C., Liu, X., Wang, X., & Jiang, H. (2024) · ACS Nano · doi:10.1021/acsnano.4c05065 · Cited by 59
Thangavelu, G., Parkman, J., Ewen, C., Uwiera, R. R. E., Baldwin, T. A., & Anderson, C. C. (2011) · Journal of Autoimmunity · doi:10.1016/j.jaut.2011.02.009 · Cited by 58
Basilious, A., & Lloyd, J. C. (2016) · Canadian Journal of Ophthalmology · doi:10.1016/j.jcjo.2015.09.008 · Cited by 56
Characterization of CD28null T cells in idiopathic pulmonary fibrosis
Habiel, D. M., Espíndola, M. S., Kitson, C., Azzara, A. V., Coelho, A. L., Stripp, B. R., & Hogaboam, C. M. (2018) · Mucosal Immunology · doi:10.1038/s41385-018-0082-8 · Cited by 64
Mittal, L., Srivastava, M., Kumari, A., Tonk, R. K., Awasthi, A., & Asthana, S. (2021) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.0c01080 · Cited by 59
Immune checkpoint inhibitors associated cardiovascular immune-related adverse events
Jo, W., Won, T., Daoud, A., & Čiháková, D. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1340373 · Cited by 55
Patsoukis, N., Weaver, J. D., Strauss, L., Herbel, C., Seth, P., & Boussiotis, V. A. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00330 · Cited by 60
Madonna, G., Ballesteros-Merino, C., Feng, Z., Bifulco, C., Capone, M., Giannarelli, D., Mallardo, D., Simeone, E., Grimaldi, A. M., Caracò, C., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2017.1405206 · Cited by 55
“by its ligands leads to T-cell inactivation and inhibition of effector function.(5,6) Tumor cells can use these physiological checkpoints in their favor and, in addition, many tumor cells can increase expression of PD-L1 in response to secretion of interferon (IFN)-g by tumor-reactive T cells infiltrating the tumor, i…”
BackgroundThe CD28–B7 Family of Co-signaling Molecules
Nagai, S., & Azuma, M. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-981-32-9717-3_2 · Cited by 62
MR cell size imaging with temporal diffusion spectroscopy
Jiang, X., Li, H., Devan, S. P., Gore, J. C., & Xu, J. (2020) · Magnetic Resonance Imaging · doi:10.1016/j.mri.2020.12.010 · Cited by 59
Thapa, M., & Carr, D. J. J. (2009) · Journal of Virology · doi:10.1128/jvi.00854-09 · Cited by 60
“Taken together, IFN- , IL-18, PDL-1, and PDL-2 do not appear to play a role.”
BackgroundInfluentialQin, S., Dong, B., Yi, M., Chu, Q., & Wu, K. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01288 · Cited by 63
PD‐1‐induced T cell exhaustion is controlled by a Drp1‐dependent mechanism
Simula, L., Antonucci, Y., Scarpelli, G., Cancila, V., Colamatteo, A., Manni, S., Angelis, B. D., Quintarelli, C., Procaccini, C., Matarese, G., et al. (2021) · Molecular Oncology · doi:10.1002/1878-0261.13103 · Cited by 57
Nanomedicine in Lung Cancer Immunotherapy
Doroudian, M., Zanganeh, S., Abbasgholinejad, E., & Donnelly, S. C. (2023) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2023.1144653 · Cited by 55
“As with PD-1 inhibitors, response rates to PD-L1 inhibitors can vary depending on factors such as PD-L1 expression levels.”
BackgroundInfluentialPredictive Biomarkers and Resistance Mechanisms of Checkpoint Inhibitors in Malignant Solid Tumors
Pavelescu, L. A., Enache, R. M., Roşu, O. A., Profir, M., Creţoiu, S. M., & Gașpar, B. S. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25179659 · Cited by 66
“The mismatch repair genes MLH1, MSH2, MSH6, and PMS2 have germline mutations or epigenetic silencing of MLH1 and account for approximately 15% of CRC with MSI [164].”
BackgroundActivation pathways that drive CD4 + T cells to break tolerance in autoimmune diseases*
Krovi, S. H., & Kuchroo, V. K. (2022) · Immunological Reviews · doi:10.1111/imr.13071 · Cited by 62
Kuo, C., Yang, C., Lin, C., Lin, G., Sytwu, H., & Chen, Y. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.111057 · Cited by 55
Iwamoto, N., Shimada, T., Terakado, H., & Hamada, A. (2016) · Journal of Chromatography B · doi:10.1016/j.jchromb.2016.04.038 · Cited by 60
Molecular Modeling Studies on the Binding Mode of the PD-1/PD-L1 Complex Inhibitors
Almahmoud, S. A., & Zhong, H. A. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20184654 · Cited by 55
“PD-1 and its ligands control the activity and tolerance of T cells, and immune-mediated tissue damage [19,20].”
BackgroundAdenosine-to-inosine RNA editing in the immune system: friend or foe?
Nakahama, T., & Kawahara, Y. (2020) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-020-03466-2 · Cited by 55
Yao, L., Jia, G., Lu, L., Bao, Y., & Ma, W. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106628 · Cited by 56
Wan, W., Huang, G., Wang, Y., Tang, Y., Li, H., Jia, C., Liu, Y., You, B.-G., & Zhang, X. (2021) · Acta Biomaterialia · doi:10.1016/j.actbio.2021.09.040 · Cited by 53
Bedke, T., Pretsch, L., Karakhanova, S., Enk, A., & Mahnke, K. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0902458 · Cited by 59
“Humans and animals with a deficiency in PD-1 expression are susceptible to autoimmune diseases (11, 12).”
BackgroundImmunotherapy in Cancer: A Combat between Tumors and the Immune System; You Win Some, You Lose Some
Rowdo, F. P. M., Barón, A., Urrutia, M., & Mordoh, J. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00127 · Cited by 55
New use of microsatellite instability analysis in endometrial cancer
Kunitomi, H., Banno, K., Yanokura, M., Takeda, T., Iijima, M., Nakamura, K., Iida, M., Adachi, M., Watanabe, K., Matoba, Y., et al. (2017) · Oncology Letters · doi:10.3892/ol.2017.6640 · Cited by 51
“Activated T cells express PD-1, and its interaction with PD-L1 decreases T cell activity (16,17).”
BackgroundTakahashi, Y., Yasui, T., Tamari, K., Minami, K., Otani, K., Isohashi, F., Seo, Y., Kambe, R., Koizumi, M., & Ogawa, K. (2017) · PLoS ONE · doi:10.1371/journal.pone.0189697 · Cited by 53
Kamo, H., Hatano, T., Kanai, K., Aoki, N., Kamiyama, D., Yokoyama, K., Takanashi, M., Yamashita, Y., Shimo, Y., & Hattori, N. (2019) · BMC Neurology · doi:10.1186/s12883-019-1416-1 · Cited by 51
Lymphatic immunomodulation using engineered drug delivery systems for cancer immunotherapy
Manspeaker, M. P., & Thomas, S. N. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.10.004 · Cited by 52
“The approval of a variety of immunotherapies, including antibodies against immune checkpoint receptors [4, 5], cancer vaccines [6], oncolytic viral therapies [7], adoptive cell therapies [8, 9], and cytokine therapies [10–12] among others [13–17] has led in some indications to remarkable clinical success in patients w…”
BackgroundDeng, M., Li, S., Fu, X., Yan, X., Chen, J., Qiu, Y., & Guo, R. (2021) · Cancer Cell International · doi:10.1186/s12935-021-02081-w · Cited by 54
Pizarro, C., García‐Díaz, D. F., Ethel Codner, D., Salas‐Pérez, F., Carrasco, E., & Pérez‐Bravo, F. (2014) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2552 · Cited by 51
Immune exhaustion during chronic infections in cattle
Konnai, S., MURATA, S., & Ohashi, K. (2016) · Journal of Veterinary Medical Science · doi:10.1292/jvms.16-0354 · Cited by 55
Neisseria gonorrhoeae Modulates Immunity by Polarizing Human Macrophages to a M2 Profile
Ortiz, M. C., Lefimil, C., Rodas, P. I., Vernal, R., López, M. N., Acuña‐Castillo, C., Imarai, M., & Escobar, A. F. (2015) · PLoS ONE · doi:10.1371/journal.pone.0130713 · Cited by 51
Moreno, B. H., Parisi, G., Robert, L., & Ribas, A. (2015) · Seminars in Oncology · doi:10.1053/j.seminoncol.2015.02.008 · Cited by 55
Yao, Z. Q., & Moorman, J. P. (2013) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-013-0219-0 · Cited by 51
“…maintain the balance between positive and the negative intracellular signals in T and B lymphocytes following antigenic encounter (Alexander 2002; Chen 2004; Egan et al. 2003; Hafler and Kuchroo 2008; Kuchroo et al. 2003; Nishimura and Honjo 2001; Okazaki and Honjo 2007; Sharpe and Freeman 2002).”
BackgroundMesenchymal stem cells suppress T cells by inducing apoptosis and through PD-1/B7-H1 interactions
Yan, Z., Zhuansun, Y., Liu, G., Chen, R., Li, J., & Ran, P. (2014) · Immunology Letters · doi:10.1016/j.imlet.2014.09.013 · Cited by 50
Faithful preclinical mouse models for better translation to bedside in the field of immuno-oncology
Saito, R., Kobayashi, T., Kashima, S., Matsumoto, K., & Ogawa, O. (2019) · International Journal of Clinical Oncology · doi:10.1007/s10147-019-01520-z · Cited by 56
Silva, P. D., Aiello, M. M., Gu‐Trantien, C., Migliori, E., Willard-Gallo, K. E., & Solinas, C. (2020) · International Journal of Cancer · doi:10.1002/ijc.33415 · Cited by 50
The role of immune checkpoints in antitumor response: a potential antitumor immunotherapy
Mejía-Guarnizo, L. V., Monroy-Camacho, P. S., Turizo-Smith, A. D., & Rodríguez-García, J. A. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1298571 · Cited by 48
“Its biological signi fi cance includes aspects related to humoral immunity, immunity against infections, transplantation immunity, hypersensitivity, and immune privilege (36).”
BackgroundRui, Y., Honjo, T., & Chikuma, S. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1315828110 · Cited by 49
“Liang SC, et al. (2003) Regulation of PD-1, PD-L1, and PD-L2 expression during normal and autoimmune responses.”
BackgroundInfluentialSakai, S., Kawamura, I., Okazaki, T., Tsuchiya, K., Uchiyama, R., & Mitsuyama, M. (2010) · International Immunology · doi:10.1093/intimm/dxq446 · Cited by 54
Tan, D., Li, S., & Yi, Q.-H. (2017) · Cancer Biomarkers · doi:10.3233/cbm-170357 · Cited by 47
“3 and encodes a 50 ∼ 55 kDa type I transmembrane glycoprotein belonging to CD28 immunoglobulin superfamily [8].”
Zheng, Y., Li, H., Chen, Z., Li, Y., Zhou, B., Hu, R., Chen, S., Xiao, H., Ma, Y., Xie, G., et al. (2022) · iScience · doi:10.1016/j.isci.2022.103785 · Cited by 55
“PD-L1 has been reported to be expressed on B cells, T cells, NK cells, macrophages, MDSCs, and DCs, and its expression is upregulated after activation (Okazaki and Honjo, 2007; Dong et al., 2019).”
BackgroundHuang, R., Dai, Q., Yang, R., Duan, Y., Zhao, Q., Haybaeck, J., & Yang, Z. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.817916 · Cited by 62
Beyond Cancer: Regulation and Function of PD-L1 in Health and Immune-Related Diseases
Beenen, A. C., Sauerer, T., Schaft, N., & Dörrie, J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23158599 · Cited by 53
“PD-L1 has been shown to be critical for the maintenance of peripheral tolerance in the context of transplantation, as blockage of the pathway led to a fastened graft rejection in CD28 and B7-1/B7-2 double deficient models.”
BackgroundInfluentialRecent advances in CAR-T cells therapy for colorectal cancer
Qin, X., Wu, F., Chen, C., & Li, Q. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.904137 · Cited by 53
Chen, Y., Guo, D.-Z., Zhu, C., Ren, S.-C., Sun, C.-Y., Wang, Y., & Wang, J. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1323797 · Cited by 56
“The interaction between PD-1 and PD-L1 is closely associated with the main mechanisms of sepsis, such as inhibiting T cells function, impairing myeloid cell function, and triggering non-immune cell death (11, 39, 40).”
BackgroundZhang, B., Yu, W., Feng, X., Zhao, Z., Fan, Y., Meng, Y., Hu, S., Cui, Y., He, Q., Zhang, H., et al. (2017) · Medical Oncology · doi:10.1007/s12032-017-0941-2 · Cited by 48
Case series of pleomorphic carcinomas of the lung treated with nivolumab
Kanazu, M., Uenami, T., Yano, Y., Nakatsubo, S., Hosono, Y., Ishijima, M., Akazawa, Y., Yamaguchi, T., Urasaki, K., Mori, M., et al. (2017) · Thoracic Cancer · doi:10.1111/1759-7714.12505 · Cited by 49
Monoclonal Antibody L 1 Mab-13 Detected Human PD-L1 in Lung Cancers
Yamada, S., Itai, S., Nakamura, T., Yanaka, M., Chang, Y.-W., Suzuki, H., Kaneko, M. K., & Kato, Y. (2018) · Monoclonal Antibodies in Immunodiagnosis and Immunotherapy · doi:10.1089/mab.2018.0004 · Cited by 47
Amicone, L., & Marchetti, A. (2018) · Translational Gastroenterology and Hepatology · doi:10.21037/tgh.2018.04.05 · Cited by 45
“The monoclonal antibody against the programmed cell death-1 (PD-1) receptor on activated T cells (nivolumab) was shown to impair its inactivating binding to the ligand PDL-1, expressed on HCC tumor cells, thus restoring T-cell-mediated antitumor response (19,20).”
BackgroundThe New Era of Cancer Immunotherapy
Khalil, D. N., Budhu, S., Gasmi, B., Zappasodi, R., Hirschhorn-Cymerman, D., Plitt, T., Henau, O. D., Zamarin, D., Holmgaard, R., Murphy, J. T., et al. (2015) · Advances in cancer research · doi:10.1016/bs.acr.2015.04.010 · Cited by 51
Liang, M., Li, J., Wang, D., Li, S., Sun, Y., Sun, T., Zhang, J., Chen, X., Li, Q., & Sun, S. (2013) · Tumor Biology · doi:10.1007/s13277-013-1006-6 · Cited by 47
“Human cancers of the lung, breast, and ovary have also been shown to aberrantly over-express the B7-H4 protein ligand [5–22].”
BackgroundInfluentialPD-1 blockage delays murine squamous cell carcinoma development
Belai, E. B., de Oliveira, C. E., Gasparoto, T. H., Ramos, R. N., Torres, S. A., Garlet, G. P., Cavassani, K. A., Silva, J. S., & Campanelli, A. P. (2013) · Carcinogenesis · doi:10.1093/carcin/bgt305 · Cited by 52
“PD-1 expression is induced by T-cell receptor signaling and is increased on activated CD4 and CD8 T cells (8,9).”
BackgroundMkrtichyan, M., Najjar, Y. G., Raulfs, E. C., Liu, L., Langerman, S., Guittard, G., Ozbun, L., & Khleif, S. N. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1103085 · Cited by 46
“The expression of PD-L2 was believed to be much more restricted and limited to the surface of activated dendritic cells and macrophages (14), although recently its expression was shown in activated human T cells and various tumor cells (15, 16).”
Wang, C., Hillsamer, P., & Kim, C. H. (2011) · BMC Immunology · doi:10.1186/1471-2172-12-53 · Cited by 57
“Programmed death-1 (PD-1 or also called CD279) is a member of the CD28 family costimulatory molecules [1,2].”
BackgroundKoh, Y. W., Jeon, Y. K., Yoon, D. H., Suh, C., & Huh, J. (2015) · Tumor Biology · doi:10.1007/s13277-015-4622-5 · Cited by 46
König, D., & Laubli, H. P. (2020) · Pharmacology · doi:10.1159/000509081 · Cited by 54
Chen, L., Jiang, X., Li, Y., Zhang, Q., Li, Q., Zhang, X., Zhang, M., Yu, Q., & Gao, D. (2022) · Clinical Immunology · doi:10.1016/j.clim.2022.108962 · Cited by 50
Ferritin-based nanomedicine for disease treatment
Zhu, Y., Zhu, Y., Cao, T., Liu, X., Liu, X., Yan, Y., Shi, Y., & Wang, J. (2023) · Medical Review · doi:10.1515/mr-2023-0001 · Cited by 49
“Programmed cell death ligand 1 (PD-L1) is another immunosuppressive molecule highly expressed on tumor cells, which binds to programmed cell death protein 1 (PD-1) on the T cells, leading to inhibition of T cell response to tumor cells [143].”
BackgroundRafiq, K., Sabir, M., Abid, M. Z., Jalil, M. A., Nadeem, M. A., Iqbal, S., Rauf, A., & Hussain, E. (2024) · Energy & Fuels · doi:10.1021/acs.energyfuels.3c04785 · Cited by 46
Qiu, J., Cheng, Z., Jiang, Z., Gan, L., Zhang, Z., & Xie, Z. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25105490 · Cited by 59
“Accumulating evidence has shown that high expression levels of PD-L1 in the TME are positively associated with poor prognosis and survival [44,45].”
BackgroundBlocking tumor escape in hematologic malignancies: The anti-PD-1 strategy
Bryan, L. J., & Gordon, L. I. (2014) · Blood Reviews · doi:10.1016/j.blre.2014.09.004 · Cited by 53
“PD ligand expression including both PD-L1 and PD-L2 onmalignant cells has been negatively correlated with prognosis for solid tumors [37].”
BackgroundPulmonary Toxicities from Checkpoint Immunotherapy for Malignancy
Possick, J. D. (2017) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2016.12.012 · Cited by 45
Yamaguchi, T., Mishima, K., Ohmura, H., Hanamura, F., Ito, M., Nakano, M., Tsuchihashi, K., Ota, S.-I., Wada, N. A., Uchi, H., et al. (2018) · Cancer Science · doi:10.1111/cas.13758 · Cited by 45
“PD‐1‐expressing T cells receive an inhibitory signal after binding to the ligands PD‐L1 and PD‐L2, expressed on APC and tumor cells, resulting in the suppression of proliferation, cytokine production, and cytotoxic activity.(7) Human anti‐ PD‐1 antibody has been developed as an anti‐tumor agent and exhibits remarkable…”
BackgroundAcquired Resistance to PD-1/PD-L1 Blockade in Lung Cancer: Mechanisms and Patterns of Failure
Pathak, R., Pharaon, R. R., Mohanty, A. R., Villaflor, V. M., Salgia, R., & Massarelli, E. (2020) · Cancers · doi:10.3390/cancers12123851 · Cited by 51
“Observations such as these [18–20], along with the findings of upregulation of PD-L1 in a variety of different solid tumors [21], led to further research and development of anti-PD-1/PD-L1”
BackgroundImmunotherapy for advanced melanoma: Fulfilling the promise
Gogas, H. J., Polyzos, A., & Kirkwood, J. M. (2013) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2013.04.006 · Cited by 54
Wang, C., Li, Y., Proctor, T. M., Vandenbark, A. A., & Offner, H. (2010) · Journal of Neuroscience Research · doi:10.1002/jnr.22181 · Cited by 44
“On the other hand, a variety of microorganisms that cause chronic infections were shown to up-regulate PD-1 expression on CD8(1) cells in individuals infected with chronic lymphocytic choriomeningitis, human immunodeficiency, and hepatitis C viruses (Barber et al., 2006; Day et al., 2006; Petrovas et al., 2006; Trautm…”
BackgroundInfluentialZhang, H., Zhang, T., You, Z., & Zhang, Y. (2015) · PLoS ONE · doi:10.1371/journal.pone.0142868 · Cited by 44
“Taku Okazaki et al demonstrated a strong correlation between PD-L1 expression on the tumor cells and a negative prognosis for human cancer patients because PD-1‒PD-L-dependent immune-inhibition is exploited by the tumors to evade the host immune system [15].”
BackgroundTherapeutic Antibodies in Cancer Therapy
Gasser, M., & Waaga-Gasser, A. M. (2016) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-32805-8_6 · Cited by 52
Aarslev, K., Dige, A. K., Greisen, S. R., Kreutzfeldt, M., Jessen, N., Vilstrup, H., Deleuran, B. W., & Grønbæk, H. (2016) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365521.2016.1233576 · Cited by 44
Han, J., Hong, Y.-K., & Lee, Y. S. (2016) · Journal of Pathology and Translational Medicine · doi:10.4132/jptm.2016.08.31 · Cited by 49
“The association between PD-1 expression on a large proportion of tumor-infiltrating lymphocytes (TILs)(5) and PD-L1 upregulation in a number of cancer cells with poor clinical outcomes makes these checkpoint molecules an attractive target for an immunotherapeutic approach.(6) Recent studies found that PD-L1 was overex…”
BackgroundPrado-García, H., Romero‐Garcia, S., Puerto-Aquino, A., & Rumbo‐Nava, U. (2017) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-017-1979-x · Cited by 50
“Programmed death ligand 1 (PD-L1) is a member of the Ig superfamily that is expressed on both hematopoietic and non-hematopoietic cells [5, 6].”
Background
Metadata
- Authors
- Okazaki, T., & Honjo, T.
- Affiliations
- Kyoto University (JP)
- ORCID
- Okazaki, T.
- Venue
- International Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2007-06-22
- Volume
- 19
- Issue
- 7
- Pages
- 813-824
- ISSN
- 0953-8178 (ISSN-L)
- 1460-2377
- OpenAlex
- W2122639773
- Cited by
- 1,310
- References
- 138
- Citations by year
- 2026: 26 · 2025: 53 · 2024: 96 · 2023: 94 · 2022: 100 · 2021: 125 · 2020: 152 · 2019: 101 · 2018: 100 · 2017: 112 · 2016: 72 · 2015: 70 · 2014: 41 · 2013: 48 · 2012: 29
- FWCI
- 1.94
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- International Immunology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Biomedical Innovation
- Japan Society for the Promotion of Science (17047024, 19689012)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- PD-1, PD-L1, PD-L2, immune checkpoint, SHP2, autoimmunity, antitumor immunity, transplantation immunity, allergy, immune privilege, clinical application
- MeSH terms
- Animals, Autoimmune Diseases, Humans, Immunity, Ligands, Antigens, CD, Intercellular Signaling Peptides and Proteins, Mice, B7-H1 Antigen, Programmed Cell Death 1 Ligand 2 Protein
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.